.png)
EVER SINCE a bite-size peanut cracker made him sputter and cough and break out in hives when he was a toddler, Carter Grodi has been under doctors orders to stay away from peanuts.
He brought his own cupcake to school birthday parties, learned to read food labels, and turned 15 without ever tasting a Kit Kat , Twix or Three Musketeers bar, all of which may contain traces of peanut because they are made in facilities that process the nuts.
But last year, carter, now 16, gorged on those candies for the first time without having reaction.
He had just completed a year long clinical trial of an oral immunotherapy regimen that aims to reduce children's sensitivity to peanut allergens by by gradually exposing them to peanut protein over the course of six months starting with minute amounts that are carefully measured and increased incrementally under medical supervision as tolerance develops.
The goal of the treatment is not to cure the allergy or enable children to eat peanut butter sandwiches, but to reduce the risk that an accidental exposure to trace amounts will trigger a life-threatening reaction in someone with a severe allergy and will relieve the fear and anxiety that go along with severe peanut allergies.
The results announced Sunday at a conference of the American College of Allergy, Asthma & Immunology in Seattle, may lead to approval of what could the first oral medication that ameliorates reactions in children with severe peanut allergies.
After six months treatment followed by six months of maintenance therapy, two-thirds of the 372 children who received the treatment were able to ingest 600 milligrams or more of peanut protein -the equivalent of two peanuts -
Without developing allergic symptoms.
By contrast, only 4 percent of the 124 children who had been given a placebo powder were able to consume the same amount of peanut without reacting.
The treatment, however, does not work for everyone.
The honor and serving of latest research on Allergies continues. The World Students Society thanks author Roni Caryn Rabin.
He brought his own cupcake to school birthday parties, learned to read food labels, and turned 15 without ever tasting a Kit Kat , Twix or Three Musketeers bar, all of which may contain traces of peanut because they are made in facilities that process the nuts.But last year, carter, now 16, gorged on those candies for the first time without having reaction.
He had just completed a year long clinical trial of an oral immunotherapy regimen that aims to reduce children's sensitivity to peanut allergens by by gradually exposing them to peanut protein over the course of six months starting with minute amounts that are carefully measured and increased incrementally under medical supervision as tolerance develops.
The goal of the treatment is not to cure the allergy or enable children to eat peanut butter sandwiches, but to reduce the risk that an accidental exposure to trace amounts will trigger a life-threatening reaction in someone with a severe allergy and will relieve the fear and anxiety that go along with severe peanut allergies.
The results announced Sunday at a conference of the American College of Allergy, Asthma & Immunology in Seattle, may lead to approval of what could the first oral medication that ameliorates reactions in children with severe peanut allergies.
After six months treatment followed by six months of maintenance therapy, two-thirds of the 372 children who received the treatment were able to ingest 600 milligrams or more of peanut protein -the equivalent of two peanuts -
Without developing allergic symptoms.
By contrast, only 4 percent of the 124 children who had been given a placebo powder were able to consume the same amount of peanut without reacting.
The treatment, however, does not work for everyone.
The honor and serving of latest research on Allergies continues. The World Students Society thanks author Roni Caryn Rabin.
0 comments:
Post a Comment
Grace A Comment!